Design, Synthesis In Vitro Anticancer Activity and Docking Studies of (−)‐Catechin Derivatives. (28th January 2015)

• Record Type: Journal Article
• Authors: Kumar, Deepak; Harshavardhan, S. J.; Chirumarry, Sridhar; Poornachandra, Y.; Jang, Kiwan; Ganesh Kumar, C.; Yoon, Yong‐Jin; Zhao, Bao‐Xiang; Miao, Jun‐Ying; Shin, Dong‐Soo
• Is Part Of: Bulletin of the Korean Chemical Society. Volume 36:Number 2(2015:Feb.)
• Page Start: 564
• Page End: 570
• Publication Date: 2015-01-28
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1002/bkcs.10108
• Languages: English
• ISSNs: 0253-2964

Abstract

<abstract abstract-type="main" id="bkcs10108-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="bkcs10108-para-0000">Novel series of ()‐catechin derivatives <bold>1a‐l</bold> were synthesized, characterized and assayed for their cytotoxicity against four selected human cancer cell lines by standard MTT assay method. Most of the compounds significantly active among which <bold>1d</bold> exhibited promising activity with IC₅₀ values of 2.5, 4.8 and 5.4 μM specifically against hepatocellular liver carcinoma (HepG2), lung adenocarcinoma (A549) and prostate (DU‐145) cell lines, while compound <bold>1j</bold> showed promising cytotoxicity against human breast adenocarcinoma MDA‐MB‐231 (IC₅₀ value of 6.6 μM). Compounds <bold>1a</bold>, <bold>1d</bold>, <bold>1e</bold>, <bold>1f</bold> and <bold>1j</bold> exhibited broad spectrum cytotoxicity against all the cell lines screened. Molecular docking studies of compound <bold>1d</bold> established the good binding affinity and are in favor of the observed biological activity. These data collectively suggest that compound <bold>1d</bold> could serve as a new template for further optimization as anticancer agent.</p> </abstract>